Who
L. Becker Hewes
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Galecto; Chief Medical Officer, Blueprint Medicines.
In numbers
- Trades disclosed
- 63
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $7.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 1 Mar 2021
- Last trade
- 5 Jan 2026
- Last filed
- 7 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jan 2026filed 7 Jan 2026 | GalectoBiotechnology | SEC FORM 4 Code A | —264,629 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | Galectooption or derivative · Biotechnology | SEC FORM 4 Code A | —528,603 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | DMRA Damora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —528,603 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | DMRA Damora TherapeuticsBiotechnology | SEC FORM 4 Code A | —264,629 at $0.00 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —13,490 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —26,125 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —9,115 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —19,271 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —25,000 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code D | —22,000 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code A | —21,353 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code D | —50,165 | filing |
| 17 Jul 2025filed 21 Jul 2025 | Blueprint Medicines | SEC FORM 4 Code U | —1,607 | filing |
| 6 Mar 2025filed 7 Mar 2025 | Blueprint Medicines | SEC FORM 4 Sold | $235K2,691 at $87.42 | filing |
| 6 Mar 2025filed 7 Mar 2025 | Blueprint Medicines | SEC FORM 4 Sold | $224K2,541 at $87.98 | filing |
| 5 Mar 2025filed 7 Mar 2025 | Blueprint Medicines | SEC FORM 4 Sold | $432K4,863 at $88.80 | filing |
| 1 Mar 2025filed 4 Mar 2025 | Blueprint Medicinesoption or derivative | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | Blueprint Medicines | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 4 Jun 2024filed 6 Jun 2024 | Blueprint Medicines | SEC FORM 4 Sold | $254K2,424 at $104.91 | filing |
| 3 Jun 2024filed 4 Jun 2024 | Blueprint Medicines | SEC FORM 4 Sold | $316K2,971 at $106.43 | filing |
News
No headline names them, or the companies they trade most, lately.